• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522.根据列线图评分进行放化疗治疗的喉癌风险组 - RTOG 0129 和 0522 的汇总分析。
Oral Oncol. 2021 May;116:105241. doi: 10.1016/j.oraloncology.2021.105241. Epub 2021 Feb 25.
2
Development and validation of nomogram models for predicting postoperative prognosis of early-stage laryngeal squamous cell carcinoma.列线图模型的建立与验证:预测早期喉鳞状细胞癌术后预后的新方法。
Curr Probl Cancer. 2024 Apr;49:101079. doi: 10.1016/j.currproblcancer.2024.101079. Epub 2024 Mar 15.
3
Development and validation of nomograms to accurately predict risk of recurrence for patients with laryngeal squamous cell carcinoma: Cohort study.列名法的开发与验证可准确预测喉鳞状细胞癌患者的复发风险:队列研究。
Int J Surg. 2020 Apr;76:163-170. doi: 10.1016/j.ijsu.2020.03.010. Epub 2020 Mar 12.
4
Development and validation of nomogram to predict risk of survival in patients with laryngeal squamous cell carcinoma.列名细胞癌患者生存风险预测列线图的开发与验证。
Biosci Rep. 2020 Aug 28;40(8). doi: 10.1042/BSR20200228.
5
[Development and validation of nomogram for predicting prognosis of patients with laryngeal squamous cell carcinoma after surgery].[预测喉鳞状细胞癌患者术后预后的列线图的开发与验证]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Dec;36(12):902-909. doi: 10.13201/j.issn.2096-7993.2022.12.003.
6
Development of comprehensive nomograms for evaluating overall and cancer-specific survival of laryngeal squamous cell carcinoma patients treated with neck dissection.用于评估接受颈部清扫术治疗的喉鳞状细胞癌患者总生存期和癌症特异性生存期的综合列线图的开发。
Oncotarget. 2017 May 2;8(18):29722-29740. doi: 10.18632/oncotarget.15414.
7
Establishment of a non-squamous cell carcinoma of the larynx nomogram prognostic model and prognosis analysis.喉非鳞状细胞癌列线图预后模型的建立及预后分析
Auris Nasus Larynx. 2022 Apr;49(2):240-247. doi: 10.1016/j.anl.2021.07.008. Epub 2021 Jul 25.
8
A nomogram to predict postoperative overall and cancer specific survival in patients with primary parotid squamous cell carcinoma: a population based study.预测原发性腮腺鳞状细胞癌患者术后总体生存率和癌症特异性生存率的列线图:一项基于人群的研究。
Sci Rep. 2025 Feb 25;15(1):6774. doi: 10.1038/s41598-025-90480-8.
9
Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer.口咽癌患者总生存和无进展生存预测列线图的开发与验证
J Clin Oncol. 2017 Dec 20;35(36):4057-4065. doi: 10.1200/JCO.2016.72.0748. Epub 2017 Aug 4.
10
Chemoradiotherapy vs radiotherapy for non-surgical locally advanced laryngeal squamous cell carcinoma patients: a propensity score-matched study and practical nomogram construction.非手术局部晚期喉鳞状细胞癌患者的化疗放疗与单纯放疗比较:一项倾向评分匹配研究及实用列线图构建
Eur Arch Otorhinolaryngol. 2024 Mar;281(3):1449-1456. doi: 10.1007/s00405-023-08360-8. Epub 2023 Dec 29.

引用本文的文献

1
Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.全面分析肝细胞癌中铜死亡相关 lncRNAs 与免疫浸润和预后的关系。
BMC Bioinformatics. 2023 Jan 3;24(1):4. doi: 10.1186/s12859-022-05091-1.
2
Value of plasma vitamin D level and nomogram model for predicting the prognosis of patients with small cell lung cancer treated with platinum plus etoposide as first-line chemotherapy.血浆维生素D水平及列线图模型对接受铂类联合依托泊苷一线化疗的小细胞肺癌患者预后的预测价值
Am J Transl Res. 2022 Nov 15;14(11):7771-7781. eCollection 2022.
3
Construction of five cuproptosis-related lncRNA signature for predicting prognosis and immune activity in skin cutaneous melanoma.构建用于预测皮肤黑色素瘤预后和免疫活性的五个铜死亡相关长链非编码RNA特征。
Front Genet. 2022 Sep 7;13:972899. doi: 10.3389/fgene.2022.972899. eCollection 2022.
4
Low LINC02147 expression promotes the malignant progression of oral submucous fibrosis.低表达 LINC02147 促进口腔黏膜下纤维性变的恶性进展。
BMC Oral Health. 2022 Jul 29;22(1):316. doi: 10.1186/s12903-022-02346-4.

本文引用的文献

1
Conditional Survival Analysis of Patients With Locally Advanced Laryngeal Cancer: Construction of a Dynamic Risk Model and Clinical Nomogram.局部晚期喉癌患者的条件生存分析:动态风险模型的构建和临床列线图。
Sci Rep. 2017 Mar 9;7:43928. doi: 10.1038/srep43928.
2
The Impact of Radiation Treatment Time on Survival in Patients With Head and Neck Cancer.放射治疗时间对头颈癌患者生存的影响
Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):967-975. doi: 10.1016/j.ijrobp.2016.08.046. Epub 2016 Sep 6.
3
Organ Preservation for Advanced Larynx Cancer: Issues and Outcomes.晚期喉癌的器官保存:问题与结果
J Clin Oncol. 2015 Oct 10;33(29):3262-8. doi: 10.1200/JCO.2015.61.2978. Epub 2015 Sep 8.
4
Total Laryngectomy Versus Larynx Preservation for T4a Larynx Cancer: Patterns of Care and Survival Outcomes.T4a期喉癌的全喉切除术与喉保留术:治疗模式与生存结果
Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):594-601. doi: 10.1016/j.ijrobp.2015.03.004.
5
Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.放射治疗肿瘤学组0129试验:一项随机III期试验,旨在测试加速分割与标准分割联合顺铂治疗头颈癌的疗效和毒性的长期报告。
J Clin Oncol. 2014 Dec 1;32(34):3858-66. doi: 10.1200/JCO.2014.55.3925. Epub 2014 Nov 3.
6
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.同步加速放疗联合顺铂加或不加西妥昔单抗治疗Ⅲ至Ⅳ期头颈部癌的随机Ⅲ期试验:RTOG 0522
J Clin Oncol. 2014 Sep 20;32(27):2940-50. doi: 10.1200/JCO.2013.53.5633.
7
Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer.RTOG9003 局部区域控制和晚期毒性的最终结果:局部晚期头颈部癌改变分割放疗的随机试验。
Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):13-20. doi: 10.1016/j.ijrobp.2013.12.027. Epub 2014 Mar 7.
8
Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy.在同步化疗治疗的头颈癌中,放疗时间延长会增加局部失败风险。
Head Neck. 2014 Aug;36(8):1120-5. doi: 10.1002/hed.23419. Epub 2013 Nov 27.
9
Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies.保留器官治疗策略治疗的喉或下咽癌中甲状腺或环状软骨侵犯的预后意义。
Radiat Oncol. 2012 Dec 21;7:219. doi: 10.1186/1748-717X-7-219.
10
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.RTOG 91-11 长期结果:局部晚期喉癌患者保喉的三种非手术治疗策略比较。
J Clin Oncol. 2013 Mar 1;31(7):845-52. doi: 10.1200/JCO.2012.43.6097. Epub 2012 Nov 26.

根据列线图评分进行放化疗治疗的喉癌风险组 - RTOG 0129 和 0522 的汇总分析。

Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522.

机构信息

Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.

Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States.

出版信息

Oral Oncol. 2021 May;116:105241. doi: 10.1016/j.oraloncology.2021.105241. Epub 2021 Feb 25.

DOI:10.1016/j.oraloncology.2021.105241
PMID:33640577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8144062/
Abstract

OBJECTIVES

To develop nomograms predicting overall survival (OS), freedom from locoregional recurrence (FFLR), and freedom from distant metastasis (FFDM) for patients receiving chemoradiation for laryngeal squamous cell carcinoma (LSCC).

MATERIAL AND METHODS

Clinical and treatment data for patients with LSCC enrolled on NRG Oncology/RTOG 0129 and 0522 were extracted from the RTOG database. The dataset was partitioned into 70% training and 30% independent validation datasets. Significant predictors of OS, FFLR, and FFDM were obtained using univariate analysis on the training dataset. Nomograms were built using multivariate analysis with four a priori variables (age, gender, T-stage, and N-stage) and significant predictors from the univariate analyses. These nomograms were internally and externally validated using c-statistics (c) on the training and validation datasets, respectively.

RESULTS

The OS nomogram included age, gender, T stage, N stage, and number of cisplatin cycles. The FFLR nomogram included age, gender, T-stage, N-stage, and time-equivalent biologically effective dose. The FFDM nomogram included age, gender, N-stage, and number of cisplatin cycles. Internal validation of the OS nomogram, FFLR nomogram, and FFDM nomogram yielded c = 0.66, c = 0.66 and c = 0.73, respectively. External validation of these nomograms yielded c = 0.59, c = 0.70, and c = 0.73, respectively. Using nomogram score cutoffs, three risk groups were separated for each outcome.

CONCLUSIONS

We have developed and validated easy-to-use nomograms for LSCC outcomes using prospective cooperative group trial data.

摘要

目的

为接受喉鳞状细胞癌(LSCC)放化疗的患者开发预测总生存期(OS)、无局部区域复发(FFLR)和无远处转移(FFDM)的列线图。

材料与方法

从 RTOG 数据库中提取 NRG 肿瘤学/RTOG 0129 和 0522 入组的 LSCC 患者的临床和治疗数据。数据集分为 70%的训练集和 30%的独立验证数据集。在训练数据集上进行单因素分析,获得 OS、FFLR 和 FFDM 的显著预测因素。使用多因素分析,结合四个先验变量(年龄、性别、T 期和 N 期)和单因素分析中的显著预测因素,构建列线图。使用训练和验证数据集的 C 统计量(c)分别对这些列线图进行内部和外部验证。

结果

OS 列线图包括年龄、性别、T 期、N 期和顺铂周期数。FFLR 列线图包括年龄、性别、T 期、N 期和时间等效生物有效剂量。FFDM 列线图包括年龄、性别、N 期和顺铂周期数。OS 列线图、FFLR 列线图和 FFDM 列线图的内部验证分别产生 c=0.66、c=0.66 和 c=0.73。这些列线图的外部验证分别产生 c=0.59、c=0.70 和 c=0.73。使用列线图评分截断值,为每个结果分离了三个风险组。

结论

我们使用前瞻性合作组试验数据为 LSCC 结果开发并验证了易于使用的列线图。